The University of Chicago Header Logo

Connection

Russell Cohen to Inflammatory Bowel Diseases

Back to Details
This is a "connection" page, showing publications Russell Cohen has written about Inflammatory Bowel Diseases.
Russell Cohen
Connection Strength
4.478
Inflammatory Bowel Diseases
  1. Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis. Dig Dis Sci. 2022 11; 67(11):5010-5013.
    View in: PubMed
    Score: 0.468
  2. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
    View in: PubMed
    Score: 0.396
  3. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):103-9.
    View in: PubMed
    Score: 0.195
  4. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):585-90.
    View in: PubMed
    Score: 0.180
  5. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007 Oct; 1(1):101-12.
    View in: PubMed
    Score: 0.166
  6. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):867-82.
    View in: PubMed
    Score: 0.157
  7. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):763-771.
    View in: PubMed
    Score: 0.143
  8. Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry. Inflamm Bowel Dis. 2025 Aug 01; 31(8):2106-2111.
    View in: PubMed
    Score: 0.143
  9. Sperm, sex, and 6-MP: the perception on conception. Gastroenterology. 2004 Oct; 127(4):1263-4.
    View in: PubMed
    Score: 0.135
  10. Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
    View in: PubMed
    Score: 0.126
  11. IBD indirect costs: the sleeping giant? Gastroenterology. 2003 Sep; 125(3):982-4.
    View in: PubMed
    Score: 0.125
  12. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 06; 29(6):1520-1529.
    View in: PubMed
    Score: 0.123
  13. IBD: the drugs work...but do the patients? Am J Gastroenterol. 2003 Apr; 98(4):722-3.
    View in: PubMed
    Score: 0.122
  14. Methotrexate in IBD--move over 6-MP? Not so fast... Gastroenterology. 2002 Nov; 123(5):1737-9.
    View in: PubMed
    Score: 0.118
  15. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.118
  16. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology. 2002 Jun; 122(7):2082-4; discussion 2084.
    View in: PubMed
    Score: 0.115
  17. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
    View in: PubMed
    Score: 0.114
  18. Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):119-32.
    View in: PubMed
    Score: 0.113
  19. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.105
  20. Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560.
    View in: PubMed
    Score: 0.101
  21. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.099
  22. The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000 Jan; 11(1):10-7.
    View in: PubMed
    Score: 0.097
  23. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.095
  24. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.094
  25. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.093
  26. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.087
  27. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.085
  28. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):99-105.
    View in: PubMed
    Score: 0.083
  29. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.082
  30. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.082
  31. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013 Dec; 19(13):2778-86.
    View in: PubMed
    Score: 0.064
  32. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex. 2006 Jul-Sep; 71(3):351-401.
    View in: PubMed
    Score: 0.038
  33. MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4.
    View in: PubMed
    Score: 0.038
  34. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):935-9.
    View in: PubMed
    Score: 0.037
  35. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):940-87.
    View in: PubMed
    Score: 0.037
  36. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 06; 57(2):281-302.
    View in: PubMed
    Score: 0.034
  37. Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
    View in: PubMed
    Score: 0.034
  38. The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.
    View in: PubMed
    Score: 0.018
  39. Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.